Duke University

The UAB Research Foundation (the University of Alabama at Birmingham)

Los Alamos National Security, LLC

Leland Stanford Junior University

The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of Pennsylvania

Boston University

Triad National Security, LLC

University of California

Feng Gao

Beatrice H Hahn

George M Shaw

Barton F Haynes

Hua-Xin Liao

Bette T Korber

Ying Ying Li

Julie Decker

Peter D Kwong

John R Mascola

Tongqing Zhou

John Mascola

Thomas B Kepler

Scott D Boyd

Rebecca M Lynch

Denise Kothe

M Anthony Moody

Peter T Hraber

Georgia D Tomaras

Stephen M Smith

Preston A Marx, Jr

David C Montefiori

Sallie Permar

Chang Yong Lu

Marie Claude Georges-Courbot

Denise L Monti

The invention provides compositions and methods to induce and boost antibody response, including but not limited to IgG responses binding to HIV-1 in a subject in need thereof, wherein the induced/boosted plasma level of the antibody responses, for example V3 and/or CD4 binding site antibody responses, is over a threshold level and is associated with reduced risk of maternal-to-child-transmission (MTCT) of HIV-1.

Methods for reducing HIV-1 mother-to-child transmission by inducing V3-specific or CD4 binding site-specific antibodies

The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.

Consensus/ancestral immunogens

The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).

Antibody evolution immunogens

In certain aspects the invention provides HIV-1 immunogens, including envelopes (CH505) and selections therefrom, and methods for swarm immunizations using combinations of HIV-1 envelopes.

Swarm immunization with envelopes from CH505

The invention relates to HIV-1 envelope polypeptides comprising the consensus envelope of SEQ ID NO: 35, compositions comprising these envelopes and methods for using same.

Modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins capable of inducing broadly reactive T- and B-cell responses

Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins

The nucleotide sequences of the genomes of eleven molecular clones for non-subtype B isolates of human immunodeficiency virus type 1 are disclosed. The invention relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and as immunogens.

Reference clones and sequences for non-subtype B isolates of human immunodeficiency virus type 1

The nucleotide sequence and deduced amino acid sequences of the complete genome of a simian immunodeficiency virus isolate from a red-capped mangabey are disclosed. The invention relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and as immunogens.

Complete genome sequence of a simian immunodeficiency virus from a red-capped mangabey

Growing community of inventors

Durham, NC, United States of America

Feng Gao